n.c.a. Lutetium-1772022-01-06T02:03:20-06:00


SHINE Technologies’ isotope production process is enabling treatment options that have the potential to improve outcomes for patients being treated for a range of cancers, such as prostate cancer. SHINE’s current focus includes production of non-carrier-added lutetium-177. The unique advantages of our n.c.a. Lu-177 production process include an exclusive processing technology, flexibility for irradiation, stable isotope enrichment capability, fewer logistical challenges in transport, and a cleaner and safer production method.

SHINE Lu-177 Product Box 3

Therapeutics in the news

Go to Top